Physician profile
Timothy Wu
NPI 1700375656
$2,135.73
in general payments reported to CMS, 2019-2025
14 companies · $282 in 2025
The $282 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2022: $569 · 2023: $634 · 2024: $546 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,462.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,461.92 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $145.96 | 2022-2023 | |
| Lilly USA, LLC | $115.69 | 2022 | |
| Alexion Pharmaceuticals, INC. | $104.32 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.73 | 2023-2024 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $49.69 | 2022-2023 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.71 | 2025 | Ofev |
| Verona Pharma, INC. | $35.00 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $29.68 | 2024 | Prolastin-C Liquid |
| Incyte Corporation | $23.79 | 2025 | Opzelura |
| Merck Sharp & Dohme LLC | $19.23 | 2024 | Verquvo |
| United Therapeutics Corporation | $18.56 | 2025 | Tyvaso |
| Dexcom, INC. | $16.34 | 2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $15.11 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.